Oxacillin
Systematic (IUPAC) name | |
---|---|
(2S,5R,6R)-3,3-dimethyl-6-[(5-methyl-3-phenyl- 1,2-oxazole-4-carbonyl)amino]-7-oxo-4-thia-1- azabicyclo[3.2.0]heptane-2-carboxylic acid | |
Clinical data | |
Trade names | Bactocill |
AHFS/Drugs.com | monograph |
MedlinePlus | a685020 |
Legal status | ? |
Identifiers | |
CAS number | 66-79-5 |
ATC code | J01CF04 QJ51CF04 |
PubChem | CID 6196 |
DrugBank | DB00713 |
ChemSpider | 5961 |
UNII | UH95VD7V76 |
KEGG | D08307 |
ChEBI | CHEBI:49566 |
ChEMBL | CHEMBL819 |
Chemical data | |
Formula | C19H19N3O5S |
Mol. mass | 401.436 g/mol |
SMILES
| |
| |
Physical data | |
Density | 1.49 g/cm³ |
Boiling point | 686.8 °C (1268 °F) |
(what is this?) (verify) | |
Oxacillin sodium (trade name Bactocill) is a narrow spectrum beta-lactam antibiotic of the penicillin class.
It was developed by Beecham.[1]
Uses
Oxacillin is a penicillinase-resistant β-lactam. It is similar to methicillin, and has replaced methicillin in clinical use. Another related compound is nafcillin. Since it is resistant to penicillinase enzymes, such as that produced by Staphylococcus aureus, it is widely used clinically in the US to treat penicillin-resistant Staphylococcus aureus. However, with the introduction and widespread use of both oxacillin and methicillin, antibiotic-resistant strains called oxacillin-resistant Staphylococcus aureus (MRSA/ORSA) have become increasingly prevalent worldwide. MRSA/ORSA is treated using vancomycin.
Adverse effects
Side effects include hypersensitivity and local reactions. In high doses, renal, hepatic, or nervous system effects can occur.[2]
References
- ↑ David Greenwood (2008). Antimicrobial drugs: chronicle of a twentieth century medical triumph. Oxford University Press US. pp. 124–. ISBN 978-0-19-953484-5. Retrieved 18 November 2010.
- ↑ Drugs.com: Bactocill
|